Abstract: An apparatus for and a method of ensuring the fit of a face mask to the face of a patient, the apparatus including a face mask having an inlet through which gas can be inhaled and a sensor for measuring the flow rate of gas drawn through the inlet of the face mask. The fit of the face mask is determined by monitoring the flow rate of gas drawn through the inlet of the face mask upon inhalation by a patient. The face mask is considered to satisfactorily fit the patient when a substantially regular inhalation waveform is achieved.
Type:
Grant
Filed:
July 29, 1998
Date of Patent:
February 27, 2001
Assignees:
Astra Aktiebolag, Medic-Aid Limited
Inventors:
Jonathan Stanley Harold Denyer, Kurt Nikander
Abstract: The invention relates to a composition comprising a first component (a) which is (R)-5-carbamoyl-8-fluoro-3-N,N-dicyclobutylamino-3,4-dihydro-2H-1-benzopyran in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof, and a second component (b) which is (+)-1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof. The invention is further directed to the preparation of the composition, pharmaceutical formulations containing said composition, and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition, as well as a kit containing said composition.
Abstract: An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antacid agents or an alginate in a fixed formulation, wherein the proton pump inhibitor is protected by an enteric coating layer and an optional separating layer in between the proton pump inhibitor and the enteric coating. The fixed formulation is in the form of multilayered tablets, sachets or multiple unit tableted dosage forms. The multiple unit dosage form is most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with dyspepsia such as heartburn.
Abstract: The invention relates to a composition comprising a first component (a) which is (R)-3N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate and a second component (b) which is 1-[3-(dimethylamino)propyl]-1-(p-fluorophenyl)-5-phthalancarbonitrile, as the racemate or an enantiomer thereof, in the form of the free base, or a pharmaceutically acceptable salt and/or solvate thereof The invention further concerns the preparation of the composition, pharmaceutical formulations containing said composition, and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition, as well as a kit containing said composition.
Abstract: The invention relates to a composition comprising a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate and a second component (b) which is a 5-HT reuptake inhibitor, excluding citalopram and paroxetine. The invention is further directed to the preparation of the composition, pharmaceutical formulations containing said composition, and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition, as well as a kit containing said composition.
Abstract: The invention relates to a composition comprising a first component (a) which is (R)-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R)-tartrate monohydrate and a second component (b) which is paroxetine, in the form of its free base, or a pharmaceutically acceptable salt and/or solvate thereof The invention is further directed to the preparation of the composition, pharmaceutical formulations containing said composition, and a method of treatment of affective disorders such as mood disorders and anxiety disorders with said composition, as well as a kit containing said composition.
Abstract: A therapeutic preparation for inhalation which comprises insulin and a substance which enhances the absorption of insulin in the lower respiratory tract, is provided in the form of a powder preparation suitable for inhalation.
Type:
Grant
Filed:
May 5, 1998
Date of Patent:
December 26, 2000
Assignee:
Astra Aktiebolag
Inventors:
Kjell Goran Erik Backstrom, Carl Magnus Olof Dahlback, Peter Edman, Ann Charlotte Birgit Johansson
Abstract: There are provided novel compounds of formula (I) ##STR1## wherein R.sup.1 represents a 2-thienyl or 3-thienyl ring and R.sup.2 represents C 1 to 4 alkyl and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are selective inhibitors of the neuronal isoform of nitric oxide synthase.
Type:
Grant
Filed:
May 21, 1998
Date of Patent:
December 26, 2000
Assignee:
Astra Aktiebolag
Inventors:
James MacDonald, James Matz, William Shakespeare
Abstract: The invention relates to a method for the determination of dose-level characteristics, such as physicochemical properties, functionality and/or quality, of a multiple unit system comprising a plurality of individual subunits (12). A number of said subunits (12) are individually analysed for obtaining precise characteristics for each individually analysed subunit (12). Said dose-level characteristics of the multiple unit system are determined based the thus-obtained precise characteristics for each individually analysed subunit (12). The invention also relates to an industrial process in which this method is used, and to the use of the claimed method in a process for designing a multiple unit system formulation product.
Type:
Grant
Filed:
June 30, 1998
Date of Patent:
December 19, 2000
Assignee:
Astra Aktiebolag
Inventors:
Staffan Folestad, Johan Gottfries, Arne Torstensson, Gunnar Zackrisson, Goran Ostling
Abstract: The present invention provides novel compounds of the formula (I):R.sub.20 --(CH.sub.2).sub.n --R (I)wherein:T.sub.20 is a bisindolylmaleimide moiety linked to the --(CH.sub.2).sub.n -group through an indolyl nitrogen,n is 0 or 1,R is a 5 or 6 membered aromatic carbocyclic or heterocyclic ring, the heterocyclic ring containing N or S,R is substituted by R.sub.1 and up to four of R.sub.2, R.sub.3, R.sub.4 and R.sub.5,wherein;R.sub.1 is aminomethyl, (N--(C.sub.1-4 -alkyl)amino)methyl, (N,N-di(C.sub.1-4 -alkyl)amino)methyl or pyridiniummethyl, andR.sub.2, R.sub.3, and R.sub.4 and R.sub.5 (if present), which may be the same or different, are each hydrogen, hydroxy, C.sub.1-4 -alkoxy, C.sub.1-4 -alkoxy) or halogen,or R.sub.2 when in a position contiguous to the bond connecting R to the --(CH.sub.2).sub.n -- group and n is 1 may, together with the 2-carbon atom on the indole to which the --(CH.sub.
Type:
Grant
Filed:
December 18, 1997
Date of Patent:
November 28, 2000
Assignee:
Astra Aktiebolag
Inventors:
H.ang.kan Bergstrand, Thomas Hogberg, Kostas Karabelas, Anders Tunek
Abstract: The present invention relates to a novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole, known under the generic name omeprazole. Further, the present invention also relates to the use of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole for the treatment of gastrointestinal disorders, pharmaceutical compositions containing it as well as processes for the preparation of the novel crystalline form of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benz imidazole.
Type:
Grant
Filed:
December 10, 1998
Date of Patent:
November 21, 2000
Assignee:
Astra Aktiebolag
Inventors:
Karin Lovqvist, Gunnel Sunden, David Noreland, Ingvar Ymen
Abstract: The invention relates to a process for the production of enantiomerically-pure AzeOH which comprises selective crystallisation of a diastereomerically-pure AzeOH-tartrate salt from a homogeneous solution of AzeOH, optically-active tartaric acid, an organic acid and an aldehyde, followed by liberation of the free amino acid.
Abstract: An inhaler for administering powder by inhalation, including an inhaler body having two ends and a peripheral wall therebetween; an inhalation unit disposed in the inhaler body, the inhalation unit comprising an inhalation channel, the inhalation channel having an air inlet and an outlet; a dosing unit disposed in the inhaler body for providing a dose of powder to the inhalation channel such that a stream of air containing powder may be drawn from the outlet of the inhalation channel on inhalation by a user; a divider having a first surface bounded by a periphery and which substantially closes one end of the inhaler body; a mouthpiece attached to the periphery of the divider, the mouthpiece having a substantially radially directed flange which provides a second surface and which, together with the first surface, defines an air chamber; a first inlet for the air chamber provided in the first surface within the periphery of the divider and in fluid communication with the outlet of the inhalation channel; a seco
Type:
Grant
Filed:
May 8, 1998
Date of Patent:
November 7, 2000
Assignee:
Astra Aktiebolag
Inventors:
Allan Dagsland, Karin Malmqvist-Granlund, Risto Virtanen
Abstract: There are provided novel compounds of formula (I) ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy.
Type:
Grant
Filed:
January 20, 1999
Date of Patent:
October 31, 2000
Assignee:
Astra Aktiebolag
Inventors:
James MacDonald, James Matz, William Shakespeare
Abstract: An oral pharmaceutical dosage form comprising an acid susceptible proton pump inhibitor and one or more antibacterial compounds in a fixed formulation. The fixed formulation is intended for oral use and in the form of an enteric coating layered tablet, an capsule or a multiple unit tableted dosage form. The multiple unit dosage form is most preferred. The new fixed formulation is especially useful in the treatment of disorders associated with Helicobacter infections.
Abstract: There is provided pharmaceutically useful compounds of formula I, ##STR1## wherein Ar.sup.1, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 have meanings given in the description, which are useful as antagonists of neuropeptide Y and in particular in the treatment of cardiovascular diseases, for example vasoconstriction.
Type:
Grant
Filed:
October 26, 1998
Date of Patent:
October 3, 2000
Assignee:
Astra Aktiebolag
Inventors:
Nils-.ANG.ke Bergman, Thomas D'Ambra, Garry M Pilling
Abstract: The present invention relates to a device for determining the correct lengths of standardized components of a dental implant system in situ in the oral cavity. The device comprises an elongate gauge body being provided with circumferential dark bands located at predetermined distances from each other and having predetermined widths, the areas between said darker bands having a pronouncedly lighter color, each boundary line between lighter and darker bands corresponding to one specific, standardized component.
Type:
Grant
Filed:
March 4, 1999
Date of Patent:
September 26, 2000
Assignee:
Astra Aktiebolag
Inventors:
Nils Gustaf Bergstrom, Leif Broberg, Anders Holmen
Abstract: New piperidinyl- or piperazinyl-substituted-1,2,3,4-tetrahydronaphthalene derivatives having the formula ##STR1## wherein X is N or CH;Y is NR.sub.2 CH.sub.2, CH.sub.2 --NR.sub.2, NR.sub.2 --CO, CO--NR.sub.2 or NR.sub.2 SO.sub.2 ;R.sub.1 is H, C.sub.1 -C.sub.6 alkyl or C.sub.3 -C.sub.6 cycloalkyl;R.sub.3 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.6 cycloalkyl or (CH.sub.2).sub.n -aryl,where aryl is phenyl or a heteroaromatic ring containing one or two heteroatoms selected from N, O and S and which may be mono- or di-substituted;n is 0-4;as (R)-enantiomer, (S)-enantiomer or a racemate in the form of the free base or a pharmaceutically acceptable salt or hydrate thereof; a pharmaceutical formulation containing the compounds, use of the compounds in the treatment of 5-hydroxytryptamine mediated disorders, processes for the preparation of the compounds and intermediates for the preparation of the compounds.
Type:
Grant
Filed:
April 25, 1997
Date of Patent:
September 26, 2000
Assignee:
Astra Aktiebolag
Inventors:
Stefan Berg, Lennart Florvall, Svante Ross, Seth-Olov Thorberg
Abstract: A novel process for the preparation of a magnesium salt of Formula I of a substituted sulfinyl heterocyclic compound containing an imidazole moiety. The process is carried out by mixing the substituted heterocycle of formula I with a weak and a magnesium source. The base and the magnesium source are selected to result in residues which are easy to remove during the reaction. The invention also relates to the use of the produced compounds in medicine.
Type:
Grant
Filed:
July 10, 1997
Date of Patent:
September 26, 2000
Assignee:
Astra Aktiebolag
Inventors:
Jan-.ANG.ke Hogberg, Panagiotis Ioannidis, Anders Mattson